PRKAA1 and neoplasm: Significantly, NPC-26-induced anti-tumor activity in vivo was remarkably weakened against HCT-116 tumors with AMPKα1 shRNA (“Seq-1”) (Figure 5A), indicating that AMPK activation could also be required for NPC-26's actions in vivo.